Transmission of paediatric respiratory syncytial virus and influenza in the wake of the COVID-19 pandemic
Eurosurveillance·
- DOI
- 10.2807/1560-7917.es.2021.26.29.2100186
- PMID
- 34296673
- PMCID
- PMC8299749
- OpenAlex
- —
- Study type
- Genomic study
- Publisher
- European Centre for Disease Control and Prevention (ECDC)
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The article identifies potential planning needs for paediatric hospital and intensive care capacity and palivizumab prophylaxis. It also discusses preparation for future influenza seasons and possible RSV vaccine implementation.
Structured evidence summary
Research question
The article examines how COVID-19-related non-pharmaceutical interventions altered paediatric respiratory syncytial virus and influenza transmission, and considers implications for European health service planning, vaccination, and surveillance.
Study design
The supplied metadata classifies the article as a genomic study. However, the abstract describes an interpretive discussion of reported transmission patterns, service-delivery implications, research opportunities, and preparedness actions rather than presenting a clearly described primary analytic study.
Population and setting
The subject concerns paediatric RSV and influenza transmission across southern and northern hemisphere countries, with implications discussed for health service delivery in Europe. The abstract does not define a participant sample or provide a specific study population.
Main findings
The abstract reports reduced RSV and influenza infections during early 2020 lockdowns in the southern hemisphere and interrupted transmission during winter 2020/21 in the northern hemisphere. It also reports delayed RSV peaks in several southern and northern hemisphere countries and describes resulting challenges for service planning, RSV vaccine trials, and influenza immunisation campaigns.
Public-health relevance
The article identifies potential planning needs for paediatric hospital and intensive care capacity and palivizumab prophylaxis. It also discusses preparation for future influenza seasons and possible RSV vaccine implementation.
Important limitations
The supplied abstract does not state explicit study limitations or provide enough methodological detail to assess the underlying evidence in depth. This summary is therefore limited to the supplied single-article abstract and metadata; the original paper is required for decision-grade interpretation.
GIDS interpretation
The article is discoverable in contexts involving transmission dynamics, surveillance, vaccination, and genomic epidemiology because its abstract discusses whole-genome sequencing, phylogenetic analysis, and data sharing as applicable to RSV and influenza surveillance. The supplied article does not establish or confirm any live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 13 auditable classifier relationships to diseases, places, topics, and study design.